Vilches-Herrera, M; Miranda-Sepúlveda, J; Rebolledo-Fuentes, M; Fierro, A; Lühr, S; Iturriaga-Vasquez, P; Cassels, BK; Reyes-Parada, M. Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors Bioorg. Med. Chem., 15 Mar 2009, 17 (6), 2452–2460. 509 kB. https://doi.org/10.1016/j.bmc.2009.01.074 #2a NMR
Rothman, RB; Blough, BE; Baumann, MH. Dual dopamine-5-HT releasers: potential treatment agents for cocaine addiction Trends Pharmacol. Sci., 1 Dec 2006, 27 (12), 612–618. 515 kB. https://doi.org/10.1016/j.tips.2006.10.006 #PAL287
Rothman, RB; Blough, BE; Baumann, MH. Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions AAPS J., 1 Mar 2007, 9 (1), E1–E10. 999 kB. https://doi.org/10.1208/aapsj0901001
Rothman, RB; Partilla, JS; Baumann, MH; Lightfoot-Siordia, C; Blough, BE. Studies of the biogenic amine transporters. 14. Identification of low-efficacy “partial” substrates for the biogenic amine transporters J. Pharmacol. Exp. Ther., 1 Apr 2012, 341 (1), 251–262. 2.2 MB. https://doi.org/10.1124/jpet.111.188946 #PAL-287
Decker, AM; Partilla, JS; Baumann, MH; Rothman, RB; Blough, BE. The biogenic amine transporter activity of vinylogous amphetamine analogs Med. Chem. Commun., 11 Aug 2016, 7 (8), 1657–1663. 605 kB. https://doi.org/10.1039/C6MD00245E #2 MS,NMR,other
Reyes-Parada, M; Iturriaga-Vasquez, P; Cassels, BK. Amphetamine derivatives as monoamine oxidase inhibitors Front. Pharmacol., 23 Jan 2020, 10 1590. 1.9 MB. https://doi.org/10.3389/fphar.2019.01590 #NIPAPAL-287